GBMA
Evergreening delays access: GBMA
Evergreening strategies delay market entry for generic medicines to the detriment of the Australian community and there is a lack of evidence to support extending market exclusivity for pharmaceuticals, according …
Delistings, shortages looming as discount well runs dry
Pharmacy is set to see more delistings and stock shortages this year as a result of simplified price disclosure, GBMA president Belinda Wood warned over the weekend. Presenting at APP2016, …
GBMA welcomes PBS listing of infliximab
The inclusion of the first monoclonal antibody biosimilar on the PBS will deliver immediate savings to the Federal Government; however the full potential of this and other biosimilar medicines relies …
GBMA welcomes the ‘a’ flagging of biosimilar infliximab
The Generic and Biosimilar Medicines Association has welcomes the recommendation by the PBAC to list biosimilar infliximab (Inflectra) on the PBS and to recommend the marking as equivalent, also known …